apelin
endogen
ligand
apelin
receptor
initi
characteris
bovin
stomach
extract
acid
preproapelin
cleav
shorter
function
fragment
includ
contain
evolutionari
conserv
acid
subsequ
identifi
predomin
isoform
apelin
famili
peptid
cardiovascular
major
circul
form
cardiovascular
system
apelin
potent
endogen
inotrop
agent
yet
apelin
modul
vascular
tone
vivo
decreas
blood
pressur
infus
rat
dilat
resist
vessel
infus
human
vitro
apelin
caus
nitric
oxidedepend
vasodil
human
splanchnic
although
nitric
oxideindepend
prostanoid
depend
vasodil
human
apelin
act
vasoconstrictor
endothelium
denud
vessel
via
direct
action
vascular
smooth
muscl
cell
whilst
also
act
potent
angiogen
factor
mitogen
endotheli
base
benefici
effect
apelin
propos
potenti
therapeut
target
cardiovascular
diseas
exampl
apelin
administr
show
cardioprotect
effect
heart
amelior
develop
pulmonari
arteri
hypertens
addit
protect
effect
apelin
report
metabol
diseas
decreas
adipos
serum
insulin
increas
insulin
renal
diseas
decreas
acut
renal
injuri
recent
emerg
apelin
protumorigen
effect
variou
cancer
model
possibl
promot
angiogenesi
inhibit
apelin
pathway
protect
tumour
howev
benefici
effect
apelin
peptid
limit
rapid
vivo
metabol
previou
studi
investig
metabol
apelin
peptid
larg
conduct
plasma
vitro
rodent
model
neither
may
repres
metabol
human
studi
demonstr
apelin
peptid
labil
plasma
halflif
less
minut
plasma
instabl
date
attribut
enzymat
activ
angiotensin
convert
enzym
ii
recent
plasma
similarli
anoth
recent
studi
report
rapid
degrad
rat
mous
plasma
compar
dog
monkey
human
plasma
author
also
confirm
find
vivo
rat
mous
identifi
ntermin
metabolit
peptid
particularli
studi
therefor
highlight
speci
differ
repertoir
proteas
circul
present
rodent
higher
mammalian
system
howev
date
studi
investig
metabol
apelin
peptid
vivo
human
aim
studi
develop
highli
sensit
mass
spectrometri
base
method
detect
quantif
apelin
peptid
plasma
use
method
measur
intact
metabolit
gener
human
follow
constant
minut
infus
peptid
found
cleav
smaller
fragment
termini
ctermin
suscept
identifi
biolog
activ
ctermin
cleavag
product
abund
well
identifi
novel
metabolit
includ
calibr
line
gener
human
plasma
data
shown
lower
limit
quantif
lloq
ngml
rel
error
calibr
standard
less
lloq
level
conform
typic
bioanalyt
method
valid
precis
accuraci
qc
sampl
show
method
robust
accur
lloq
sampl
return
coeffici
variat
cv
whilst
qc
level
cv
repres
chromatogram
obtain
calibr
standard
shown
fig
sampl
obtain
infus
chromatograph
peak
observ
peptid
fig
b
sampl
obtain
end
infus
minut
show
strong
peak
minut
correspond
fig
measur
concentr
sampl
minut
ngml
addit
data
six
donor
control
sampl
receiv
apelin
infus
show
endogen
level
apelin
sampl
lloq
see
supplementari
fig
peak
height
obtain
chromatogram
donor
sampl
maximum
height
seen
lloq
consid
blank
quantit
purpos
base
fda
method
valid
guidelin
demonstr
select
lcm
order
identifi
potenti
metabolit
gener
minut
infus
period
sampl
reanalys
use
high
resolut
mass
spectromet
full
scan
lcm
data
interrog
potenti
deriv
metabolit
compar
extract
ion
chromatogram
analyt
minut
sampl
qualbrows
softwar
packag
thermofish
peptid
identifi
minut
sampl
mainli
gener
loss
ctermin
amino
acid
fig
rel
abund
sampl
display
fig
notabl
abund
fragment
known
biolog
metabolit
identifi
although
lower
level
parent
includ
like
biolog
inact
chromatograph
spectra
correspond
metabolit
shown
fig
addit
abund
metabolit
identifi
fig
fig
present
suffici
level
gener
suitabl
product
ion
spectra
allow
experiment
acquir
fragment
match
theoret
fragment
peptid
sequenc
rel
mass
accuraci
potenti
metabolit
gener
experiment
valu
within
ppm
expect
valu
whilst
mass
accuraci
parent
peptid
highest
valu
ppm
oxid
methionin
residu
identifi
howev
sinc
modif
also
observ
extract
standard
could
ascertain
occur
vivo
artefact
extract
process
use
approach
describ
sever
ntermin
metabolit
identifi
fig
note
peak
area
fragment
lower
compar
observ
ctermin
fragment
abund
ntermin
fragment
observ
fig
b
fragment
present
low
abund
includ
mass
accuraci
experiment
acquir
monoisotop
mz
metabolit
shown
fig
within
ppm
expect
valu
develop
valid
high
resolut
lcmsm
method
detect
quantif
rel
quantif
metabolit
vivo
human
plasma
shown
method
robust
reproduc
high
sensit
lloq
ngml
use
method
quantifi
intact
peptid
constant
infus
minut
healthi
volunt
show
first
time
human
vivo
cleav
n
ctermini
cterminu
suscept
proteolyt
activ
abund
metabolit
identifi
method
high
level
also
detect
sequenc
confirm
use
tandem
mass
spectrometri
manual
product
ion
match
discoveri
cleav
end
unexpect
sinc
date
cleavag
cterminu
find
may
therefor
better
explain
extrem
unstabl
natur
apelin
peptid
worth
note
cterminu
suscept
proteolyt
activ
nterminu
whose
metabolit
present
approxim
lower
level
may
partli
explain
pyroglutamyl
nterminu
may
protect
region
enzymat
activ
degre
nterminu
also
contain
rprl
motif
critic
bind
apelin
henc
cleavag
direct
like
profoundli
affect
affin
ntermin
fragment
receptor
previou
studi
show
vitro
neprilysin
cleav
amino
therebi
make
neprilysin
first
enzym
identifi
date
complet
inactiv
peptid
importantli
shown
studi
presenc
one
propos
neprilysin
cleavag
product
human
vivo
addit
evid
cleavag
scissil
bond
given
detect
ctermin
fragment
date
studi
investig
metabol
peptid
vivo
human
interestingli
like
arginin
vasopressin
also
propos
cleav
vivo
c
n
termini
carboxypeptidas
postprolin
enzym
cleav
cterminu
arginin
vasopressin
aminopeptidas
cleav
ntermin
contrast
vivo
studi
natur
identifi
singl
terminu
cleavag
peptid
growth
hormonereleas
liraglutid
glucagonlik
big
previou
vitro
studi
plasma
suggest
metabolit
produc
enzymat
activ
result
remov
ctermin
howev
unclear
whether
metabolit
retain
biolog
activ
apelin
receptor
one
studi
argu
reduc
biolog
activ
compar
nativ
measur
hypotens
effect
howev
yang
et
demonstr
metabolit
contract
human
saphen
vein
subnanomolar
potenc
potent
posit
inotrop
pace
mous
human
heart
ex
vivo
author
demonstr
present
endogen
endothelium
human
heart
lung
went
show
biolog
activ
vivo
human
similarli
previou
studi
report
cleav
vivo
consist
studi
work
provid
clear
evid
produc
endogen
human
plasma
vivo
possibl
via
activ
also
cleav
result
gener
enzym
respons
produc
metabolit
remain
unknown
correspond
ntermin
fragment
ctermin
metabolit
also
identifi
data
consist
previou
vivo
studi
male
rat
also
identifi
ctermin
author
report
accumul
signal
time
signal
decreas
suggest
follow
cleavag
unidentifi
enzym
subsequ
cleav
metabolit
retain
rprl
motif
requir
although
unclear
retain
biolog
activ
taken
togeth
find
may
suggest
least
common
metabol
pathway
rat
human
vivo
studi
requir
identifi
specif
proteas
involv
inhibit
degrad
enzym
wellestablish
strategi
gener
therapeut
agent
import
member
reninangiotensin
system
convert
angiotensinii
angiotensin
latter
mediat
vasodilat
antiprolifer
antiapoptosi
antifibrot
addit
implic
heart
diabet
acut
lung
lung
injuri
induc
lethal
avian
influenza
respiratori
syncyti
sever
acut
respiratori
syndrom
sar
recent
gsk
develop
recombin
human
treatment
acut
respiratori
distress
syndrom
ard
show
molecul
welltoler
clinic
corrobor
apelin
signal
induc
express
fail
protect
lung
injuri
experiment
model
acut
respiratori
distress
possibl
inhibit
pathway
compon
furthermor
apelin
counteract
effect
angiotensinii
signal
neg
regul
suggest
target
apelin
could
potenti
novel
therapeut
strategi
treatment
lung
injuri
relat
patholog
heart
failur
benefici
effect
apelin
heart
failur
well
characteris
plasma
apelin
level
suggest
increas
earli
heart
failur
decreas
late
stage
support
heart
failur
therapi
cardiac
resynchronis
therapi
use
treat
refractori
chronic
heart
failur
shown
increas
plasma
apelin
suggest
increas
apelin
level
associ
improv
therapeut
apelin
administr
increas
stroke
volum
contractil
fail
therebi
improv
perform
fail
heart
similarli
neprilysin
inhibitor
emerg
pivot
therapeut
strategi
clinic
manag
heart
failur
due
role
neprilysin
degrad
vasoact
peptid
includ
natriuret
peptid
inde
neprilysin
inhibitor
sacubitril
use
clinic
manag
heart
data
may
therefor
suggest
addit
benefit
neprilysin
inhibitor
heart
failur
reduc
apelin
inactiv
result
benefici
vasodil
increas
contractil
cardiac
output
build
find
studi
could
substitut
amino
acid
neprilysin
cleavag
site
unnatur
amino
acid
improv
resist
degrad
inde
recent
shown
infus
neprilysin
resist
establish
mice
model
abdomin
aortic
aneurysm
amelior
advers
aortic
remodel
aneurysm
strategi
also
demonstr
significantli
increas
resist
suggest
could
potenti
mechan
improv
plasma
stabil
apelinbas
therapeut
clinic
indic
recent
publish
anoth
approach
stabilis
apelin
peptid
human
blood
use
albumin
domain
albudab
antibodi
conjug
apelin
analogu
show
peptid
resist
degrad
yet
retain
biolog
activ
human
apelin
receptor
vitro
therefor
strategi
could
near
futur
result
develop
first
apelinbas
therapeut
treatment
human
diseas
conclus
apelin
peptid
protect
role
cardiovascular
diseas
howev
potenti
therapeut
use
impair
poor
plasma
stabil
peptid
studi
develop
highli
sensit
method
detect
quantif
human
plasma
first
time
human
vivo
identifi
abund
metabolit
cleavag
product
previous
demonstr
retain
signific
biolog
activ
addit
put
neprilysin
metabolit
combin
inhibit
neprilysin
may
novel
strategi
enhanc
endogen
apelin
level
condit
peptid
downregul
addit
data
inform
design
stabl
apelin
peptid
therapeut
use
custom
synthesis
severn
biotech
kidderminst
england
analys
mass
spectrometri
puriti
hplc
analysi
dispens
steril
condit
pharmacolog
activ
confirm
use
vitro
vivo
assay
supplementari
fig
peptid
store
monitor
freezer
stabl
isotop
label
pglur
r
shkgpmpfacid
custom
synthesis
cambridg
research
biochem
billingham
england
protein
lobind
eppendorf
tube
cat
ml
protein
lobind
plate
cat
purchas
eppendorf
stevenag
uk
oasi
hlb
prime
plate
purchas
water
water
wilmslow
uk
cat
acetonitril
acn
cat
glacial
acet
acid
cat
purchas
sigma
aldrich
saint
loui
usa
methanol
cat
formic
acid
fa
water
vv
cat
purchas
fisher
scientif
new
hampshir
usa
acquiti
uplc
hss
mm
column
cat
use
lcmsm
analysi
obtain
water
wilmslow
uk
studi
regist
clinicaltrialsgov
carri
ethic
approv
yorkshir
humber
sheffield
research
ethic
committe
rec
refer
particip
gave
written
inform
consent
studi
adher
declar
helsinki
six
healthi
volunt
male
femal
mean
age
bodi
mass
index
within
normal
rang
recruit
infus
volunt
fast
lie
supin
head
support
quiet
temperatur
control
room
durat
studi
follow
period
acclimatis
first
sampl
venou
blood
obtain
arm
contralater
arm
use
infus
apelin
vial
contain
allow
warm
room
temperatur
dilut
physiolog
salin
produc
stock
solut
filter
use
portex
flat
filter
portex
uk
undergo
serial
dilut
steril
salin
loss
apelin
follow
filtrat
procedur
volunt
infus
concentr
nmolmin
rate
mlmin
minut
use
syring
pump
equip
ml
syring
gaug
cathet
second
venou
sampl
obtain
immedi
end
infus
blood
sampl
collect
ml
edta
tube
immedi
put
wet
ice
centrifug
minut
rpm
store
prior
analysi
previou
studi
use
concentr
nmolmin
system
infus
obtain
therapeut
respons
patient
pulmonari
arteri
hypertens
highest
dose
well
dose
chosen
nmolmin
slightli
higher
order
identifi
possibl
metabolit
addit
control
sampl
obtain
donor
male
femal
within
similar
age
group
receiv
apelin
infus
comparison
lcmsm
method
develop
stabl
isotop
label
analogu
lcmsm
instrument
use
quantit
includ
hclass
acquiti
water
attach
tqx
tripl
quadrupol
mass
spectromet
water
peptid
separ
use
mm
mm
particl
hss
acquiti
column
held
flow
gradient
start
condit
fa
water
vv
b
fa
acn
start
condit
held
minut
rais
b
minut
column
flush
b
minut
return
start
condit
total
time
analysi
minut
first
minut
last
minut
divert
wast
sourc
paramet
use
includ
posit
electrospray
voltag
kv
ga
flow
lhour
desolv
temperatur
cone
voltag
v
full
scan
analysi
peptid
show
h
charg
state
predomin
ion
spectrum
previous
describ
mesmin
et
lcmsm
analysi
therefor
select
fragment
product
ion
spectrum
collect
rang
mz
two
ion
select
srm
optimis
mz
ion
correspond
fragment
ion
deriv
loss
methylsulphid
group
methionin
ion
previous
describ
mesmin
et
optim
condit
two
srm
transit
collis
energi
valu
ev
respect
intern
standard
use
collis
energi
target
transit
peptid
peak
area
integr
use
targetlynx
program
associ
masslynx
v
water
peak
area
ratio
gener
correspond
stabl
isotopelabel
intern
standard
peptid
peak
plasma
sampl
thaw
ice
transfer
protein
lobind
eppendorf
tube
contain
guhcl
aliquot
acn
water
contain
ngml
intern
standard
ad
plasma
sampl
vortex
centrifug
x
g
minut
precipit
plasma
protein
supernat
transfer
ml
protein
lobind
plate
evapor
sampl
reconstitut
fa
vv
load
onto
oasi
hlb
prime
plate
water
wilmslow
uk
slowli
extract
posit
pressur
manifold
water
column
wash
methanol
water
acet
acid
vv
elut
cartridg
use
methanol
water
acet
acid
vv
eluat
evapor
dryness
reconstitut
fa
vv
water
inject
onto
lcmsm
system
blank
plasma
preincub
least
hour
degrad
endogen
use
gener
eight
point
calibr
line
custom
synthesis
rang
ngml
aliquot
calibr
standard
ngml
extract
use
spe
method
describ
four
level
qc
also
gener
ngml
extract
six
time
order
assess
precis
accuraci
method
calibr
line
follow
linear
fit
weight
appli
recoveri
plasma
assess
analys
spike
solut
extract
concentr
ngml
plasma
sampl
six
individu
also
extract
assess
select
lcmsm
method
sampl
reanalys
high
resolut
mass
spectromet
identifi
potenti
metabolit
administ
peptid
full
scan
analysi
perform
use
thermoscientif
ultim
lc
system
connect
thermoscientif
orbitrap
qexact
plu
mass
spectromet
solvent
use
separ
fa
water
vv
b
fa
acn
vv
volum
extract
inject
onto
hss
mm
water
elstre
uk
held
flow
rate
start
condit
b
use
captur
hydrophil
peptid
metabolit
elut
use
linear
gradient
b
minut
column
wash
minut
b
return
start
condit
minut
total
run
time
minut
mass
spectrometri
perform
use
posit
electrospray
mode
needl
voltag
kv
ga
set
sheath
ga
aux
ga
flow
rate
temperatur
ga
set
transfer
capillari
valu
v
full
scan
data
acquir
mz
rang
use
resolut
maximum
fill
time
ms
acquir
lcm
data
interrog
potenti
metabolit
search
potenti
cleavag
product
parent
peptid
raw
data
file
use
qualbrows
softwar
packag
thermofish
mz
valu
peptid
multipl
charg
state
display
supplementari
tabl
potenti
metabolit
manual
identifi
subsequ
characteris
sampl
reinject
use
target
msm
analysi
potenti
peptid
target
use
precursor
ion
mz
valu
collis
energi
collis
energi
respect
msm
analysi
involv
lc
separ
msm
data
acquir
resolut
agc
ion
lowest
mz
valu
max
fill
time
ms
